Press Releases

Press Releases
Date Title and Summary View
Jul 28, 2016 LEXINGTON, Mass., July 28, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, today announced that the Company will release its first quarter 2016 financial results on Thursday, August 4, 2016, before th...
Jun 21, 2016 LEXINGTON, Mass., June 21, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced that the first patient was dosed in a Phase 1 trial of CA-170. CA-170 is a first-in-class, ...
Jun 2, 2016 LEXINGTON, Mass., June 02, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, today announced that Dr. Ali Fattaey, President & Chief Executive Officer, will present at the Jefferies Healthcare Conferenc...
Jun 2, 2016 LEXINGTON, Mass., June 02, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced that a Phase 2 trials-in-progress poster for CUDC-907, Curis' proprietary drug candidate in development f...
Jun 1, 2016 LEXINGTON, Mass., June 01, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's Investigational ...
May 9, 2016 LEXINGTON, Mass., May 09, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, today reported its financial results for the first quarter ended March 31, 2016. "...
May 2, 2016 LEXINGTON, Mass., May 02, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, today announced that the Company will release its first quarte...
Apr 20, 2016 LEXINGTON, Mass., April 20, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, today announced that Curis and its collaborator, Aurigene, presented data from the following  program...
Apr 11, 2016 LEXINGTON, Mass., April 11, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, today announced that Curis scientists and its collaborator, Aurigene will present data from multiple programs ...
Apr 4, 2016 -- Latest analysis of data presented at the American Society of Hematology's annual meeting in December, 2015 ---- CUDC-907 demonstrated objective responses, including complete responses, in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) -- LEXINGTON, Mass....
FirstPrevious
3
... NextLast
Add to Briefcase = add release to Briefcase